Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 21, 2014; 20(3): 684-698
Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.684
Table 1 World Health Organization-based classification of mucosa-associated lymphoid tissue lymphomas
Hierarchical classification
Tumors of hematopoietic and lymphoid tissue
Mature B-cell neoplasms
Non-Hodgkin (B-cell) lymphomas
Marginal zone (B-cell) lymphomas
Extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue
Table 2 Recurrent chromosomal translocations described in mucosa-associated lymphoid tissue lymphomas
TranslocationFusion protein
t(11;18) (q21;q21)API2-MALT1
t(1;14) (p22;q32)BCL10-IGH
t(1;2) (p22;p12)BCL10-IGK
t(14;18) (q32;q21)IGH-MALT1
t(3;14) (p14;q32)FOXP1-IGH
Table 3 Useful phenotypic markers for the differential diagnosis of mucosa-associated lymphoid tissue lymphoma
sIg+B-cell receptor
CD19+Pan-B-cell marker
CD20+Pan-B-cell marker
CD22+Pan-B-cell marker
CD79a+Pan-B-cell marker
CD5-Positive in CLL/SLL
CD10-Positive in follicular lymphoma
CD23-Positive in CLL/SLL
Cyclin D1-Positive in mantle cell lymphoma
Table 4 Association between abdominal computerized tomography findings and the likelihood of low-grade and high-grade lesions
Low-grade lesionsHigh-grade lesions
Normal scansAbnormal scans
Gastric wall thickening < 5-10 mmDiffuse gastric wall thickening > 10 mm
Small depressed lesions with vague marginsWell-demarcated masses with homogeneous attenuation and mild contrast enhancement
Perigastric adenopathies more likely
Table 5 Comparison of four frequently used staging systems for primary gastrointestinal lymphomas
Tissue invasionAnn arborRadaszkiewiczLuganoParis
Gastrointestinal tractIEIEIT1 N0 M0
Mucosa or submucosaIEIE1IT1 N0 M0
MucosaIEIE1IT1m N0 M0
SubmucosaIEIE1IT1sm N0 M0
Muscularis propria or subserosaIEIE2IT2 N0 M0
SerosaIEIE2IT3 N0 M0
Intra-abdominal extensionII
Adjacent tissues or organsIEIEIIET4 N0 M0
Regional lymph nodesIIEIIEII1T1 N1 M0
Infradiaphragmatic distal lymph nodesIIEIIEII2T1 N2 M0
Disseminated diseaseIV
Supradiaphragmatic lymph nodesIIIEIIIEIVT1 N3 M0
Non-contiguous gastrointestinal2IVEIVEIVT1 N1 M1
Non-contiguous metastasis3IVEIVEIVT1 N1 M2
Marrow involvementIVEIVEIVET1 N1 M1B1
Table 6 Tumor-node-metastasis staging system qualifiers
TumorTxExtension of lymphoma not established
T0No evidence of primary lymphoma
NodesNxNodal involvement not evaluated
N0No evidence of nodal involvement
MetastasisMxDissemination of lymphoma not evaluated
M0No evidence of lymphoma dissemination
Bone marrowBxBone marrow infiltration not evaluated
B0No evidence of bone marrow infiltration
Table 7 International prognostic index for aggressive B-cell lymphomas
Prognostic factorQuantification
Advanced age> 60 yr
Advanced stageAnn arbor stages III or IV
High tumor burden and activityIncreased serum lactate dehydrogenase
Poor performance statusECOG ≥ 2
Multifocal distributionTwo or more extranodal sites
Table 8 Chemotherapy treatment options in American and European guidelines
Drug groupDrugs
Purine nucleoside analoguesFludarabine12
Anthracyclines and anthracenedionesDoxorubicin2
Vinca alkaloidsVincristine2